Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

... the development of novel therapeutics for heart failure patients, today announced dosing of its first ... for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. ... ability to relieve symptoms of acute heart failure and its effects on biomarkers of ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec(R) did ... (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% ... patients. The primary endpoint is the treatment failure rate at Study Day 80. This endpoint was ...

Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate

... A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate. Palatin expects the patent will ... pharmacodynamic properties. About Heart failure Heart failure affects over 5.7 million people in the United ...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

... that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that ... implantation of MyoCell SDF-1 in congestive heart failure patients post myocardial infarction(s). ... to test this promising product candidate in heart failure patients after completing very successful ...

Novel gene found for dilated cardiomyopathy

... for heart muscle disease and chronic heart failure in some children and adults with dilated ... which is the most common cause of chronic heart failure in young people and the most common reason for ... About one in three cases of congestive heart failure is due to DCM, which also occurs in children. ....

Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement

... the development of novel therapeutics for heart failure patients, today announced that it has received ... for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. ... ability to relieve symptoms of acute heart failure and its effects on biomarkers of ...

Hill-Rom Announces Sale of Negative Pressure Wound Therapy Intellectual Property

... exposure to product liability or other claims, failure of the Company's announced or future strategic ... recent spin-off of the funeral service business, failure to realize the anticipated benefits of the spin-off, failure of the Company to execute its acquisition and ...

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout

... gout. Refractory chronic gout or treatment failure gout (TFG) is gout in patients who have failed to ... as a therapy for patients with treatment failure gout, to control hyperuricemia and to manage the ... of the Advisory Committee; any delay or failure by us in completing the development of KRYSTEXXA; ...

Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter

... when anticoagulant therapy is contraindicated, failure of anticoagulant therapy in thromboembolic ... governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse ... in business strategy or development plans; our failure to obtain patent protection for discoveries; loss ...

PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice

... Function in Dogs with Advanced Chronic Heart failure NEW YORK, June 3 /PRNewswire/ -- PeriCor ... by Hani N. Sabbah, Ph.D., at the European Heart failure Congress 2009 in Nice, France. The study was ... adjunct therapy for the treatment of acute heart failure syndromes. GP531 represents a novel ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... by the significant increase in risk of cardiac failure associated with high cumulative doses of these ... heart damage that may result in congestive heart failure many years later. As a result, there is a ... including, without limitation, the potential failure of pixantrone to prove safe and effective (or ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to ... Myocardial damage may lead to congestive heart failure and may occur as the total cumulative dose of ... carefully monitored Congestive heart failure or cardiomyopathy may occur after discontinuation ...

Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million

... of arteriovenous fistula (AVF) maturation failure and arteriovenous graft (AVG) failure in patients with end-stage renal disease who are ... through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to ...

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

... has potential utility in the treatment of heart failure patients around the world. We intend to move this ... CK-1827452 for the potential treatment of heart failure across the continuum of care, in both hospital ... a Late Breaking Trial session at the 2009 Heart failure Congress of the European Society of Cardiology, ...

Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial

... patients are expected to develop congestive heart failure (CHF). At cumulative doses of doxorubicin in ... heart damage that may result in congestive heart failure many years later. As a result, there is a ... including, without limitation, the potential failure of pixantrone to prove safe and effective for ...

Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA

... the development of novel therapeutics for heart failure patients, received notification from the U.S. ... for up to 72 hours in patients with acute heart failure and renal insufficiency. The dosing of the study ... designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac ...

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

... in the completion of Vanda's clinical trials; a failure of Vanda's products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or ... of Vanda's products in the marketplace, or a failure to become or remain profitable; Vanda's ...

Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions

... into Percent Biventricular Pacing in Heart failure Patients. David L. Hayes, M.D., will present on ... for mortality among various sub-groups of heart failure patients receiving CRT therapy. The results will ... support pacing on clinical outcomes in heart failure patients receiving CRT-D devices. The results ...

Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout

... a novel biological drug for treatment failure gout (TFG) patients, will be reviewed by the ... of pegloticase therapy in patients with treatment failure gout, under the auspices of an SPA from the FDA. ... KRYSTEXXA(TM) (pegloticase) for treatment failure gout has reported positive Phase 1, 2 and 3 ...

Savient Pharmaceuticals Reports First Quarter 2009 Financial Results

... functional disability in patients with treatment failure gout appeared in the Journal of Rheumatology. ... to treat the disabling aspects of the treatment failure gout population." Financial Results of ... KRYSTEXXA(TM) (pegloticase) for treatment failure gout has reported positive Phase 1, 2 and 3 ...

University of Illinois Medical Center in Chicago First Hospital to Install Innovative Shape-HF™ Cardiopulmonary Testing System

... measure cardiopulmonary gas exchange in heart failure patients. It can make a dramatic difference in ... and ventilation in patients with chronic heart failure and other cardiopulmonary disease. While gas ... the device. "It broadens the pool of heart failure patients we are able to accurately test because ...

Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients

... Quality of Life and Disability in Treatment failure Gout Patients EAST BRUNSWICK, N.J., May 5 ... study of patients with treatment failure gout (TFG). The objective of the study was to ... the quality of life in patients with treatment failure gout and appears in the May issue of the Journal ...

Vanda Pharmaceuticals Reports First Quarter 2009 Results

... in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or ... product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability ...

Medco Delivers First-Quarter 2009 GAAP Diluted EPS of $0.58; Diluted EPS Excluding Amortization of Intangible Assets of $0.63; Reaffirms 2009 EPS Guidance; Announces Win of Coventry Commercial Business Starting January 1, 2010

... ability to attract and retain clients; failure to retain key clients and their members, either ... services or to reduced profitability; failure in continued execution of our Medicare Part D ... operation and technology infrastructure and failure to execute could adversely impact our business; ...

Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy

... or reverse the progression of congestive heart failure in patients who have an enlarged left ventricle. ... impressive efficacy. Given that congestive heart failure is a lethal and complex disease, positive ... or reverse the progression of chronic heart failure (CHF) and mitral valve regurgitation (MR), ...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... malignancy. Worsening congestive heart failure (CHF) and new onset CHF have been reported with ... be used with caution in patients with heart failure and should be discontinued if new or worsening symptoms of heart failure appear. TNF-blocking agents, including SIMPONI, ...

The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure

... the April 2009 issue of the Journal of Cardiac failure . The CUPID clinical trial demonstrated ... the prognosis of patients with chronic heart failure remains extremely poor. Moreover, heart ... total of 9 patients with NYHA Class III/IV Heart failure received a single intracoronary infusion of ...

Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure

... the development of novel therapeutics for heart failure patients, announced today that, in the course of ... from the Phase IIa clinical trial in acute heart failure patients. About CD-NP CD-NP is a novel ... and preserve or enhance renal function in heart failure patients. In addition to an initial indication ...

WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results

... anticipate include our limited operating history; failure to generate sufficient future cash flows or ... future financing on acceptable terms or at all; failure to retain key personnel; effective integration of ... high percentage of our revenues; risk of payment failure by any of our large customers, which could ...

Publication of Shire plc's Annual Report 2008

... and - product liability claims. The failure to obtain and maintain reimbursement, or an ... likely to have a high annual cost of therapy. The failure to obtain and maintain pricing and reimbursement ... capability. In the event of either the Group's failure or ...

Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives

... the development of novel therapeutics for heart failure patients, today announced that, pursuant to ... differentiate CD-NP from other acute heart failure therapies. Through financing, partnering ... placebo-controlled Phase 2b acute heart failure Proof of Concept study. About ...

VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities

... statements include the following: any failure of the bids for the purchase of the assets of the ... creditors, the Bankruptcy Court or otherwise; any failure of the Company and each of the successful bidders ... sale agreement for the assets to be acquired; any failure of a successful bidder to consummate the purchase ...

New Insights into the Mechanism of Action of Antipsychotic Drugs

... in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or ... product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability ...

Nile Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results and Announces Conference Call on March 10, 2009

... the development of novel therapeutics for heart failure patients, today announced its fourth quarter and ... blood pressure and renal function in stable heart failure patients, and also starting and completing a ... and renal effects of CD-NP in acute heart failure patients. Nile believes that the results of these ...

KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure

... effects on late-stage congestive heart failure showed that the newly available pre-converted ... prognosis for patients with NYHA Class IV heart failure is very poor, with mortality rates as high as 74 ... seven patients with end-stage congestive heart failure was associated with overall clinical improvement. ...

Cordex Pharma Forms Heart Failure Medical Advisory Board

... Disorders and The Center for Advanced Heart failure Care at Hahnemann University Hospital. ... Cordex's President and CSO. "Progressive heart failure is a growing and vexing medical problem around ... drug available to treat the desperately ill heart failure patients worldwide." About ...

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results

... in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or ... product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability ...

Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29

... The risk of sudden cardiac death in heart failure patients is six to nine times greater than that of the general population. Heart failure is responsible for 280,000 deaths annually in the ... and the nitric oxide/redox imbalance in heart failure as a novel target for drug development," said Dr. ...

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

... in humans and has demonstrated efficacy in heart failure in several open-label Phase 2 trials. To date ... exhibit a clean safety profile. About Heart failure Heart failure is a complex clinical syndrome that can result ...

ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference

... genetically-targeted therapies for heart failure and other cardiovascular diseases, and Nuvelo, ... genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's ... and mild vasodilator being developed for heart failure and other indications. ARCA has identified common ...